Key points from article :
Dutch biotech startup Mair Therapeutics has launched with a focus on developing new treatments for neurodegenerative diseases, starting with Parkinson’s. Based in Nijmegen, the company is using advanced computational modelling and drug discovery technologies to accelerate the development of potential therapies. A key part of its approach involves targeting the lysosomal ion channel TMEM175, which plays a crucial role in regulating cellular processes linked to Parkinson’s pathology.
Research suggests that TMEM175 is involved in mitochondrial and lysosomal function, as well as the processing of α-synuclein, a protein closely associated with Parkinson’s. Given its genetic link to Parkinson’s risk, the channel is seen as a promising therapeutic target. Mair is collaborating with local experts, including Radboud University Medical Center’s Parkinson’s research center and the Kuijpers Lab at the Donders Institute, which specializes in synaptic function.
The startup has secured pre-seed funding from Torrey Pines Investment and Oost NL, organizations that support early-stage biopharmaceutical innovation. It is also part of the Expert Systems accelerator, which integrates artificial intelligence with human expertise to advance preclinical drug discovery. With this combination of cutting-edge technology and strategic partnerships, Mair aims to make a significant impact in the search for Parkinson’s treatments.
